Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(7 years from now) |
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(4 years from now) |
Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic